APH vs. BXP, AGY, ANCR, CEL, EAH, VLG, BMK, HVO, OXB, and TSTL
Should you be buying Alliance Pharma stock or one of its competitors? The main competitors of Alliance Pharma include Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), Animalcare Group (ANCR), Celadon Pharmaceuticals (CEL), ECO Animal Health Group (EAH), Venture Life Group (VLG), Benchmark (BMK), hVIVO (HVO), Oxford Biomedica (OXB), and Tristel (TSTL). These companies are all part of the "medical" sector.
Alliance Pharma (LON:APH) and Beximco Pharmaceuticals (LON:BXP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Alliance Pharma received 95 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. However, 64.67% of users gave Beximco Pharmaceuticals an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.
Alliance Pharma has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Beximco Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Beximco Pharmaceuticals has a net margin of 11.80% compared to Alliance Pharma's net margin of -4.15%. Beximco Pharmaceuticals' return on equity of 10.29% beat Alliance Pharma's return on equity.
Beximco Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Alliance Pharma currently has a consensus price target of GBX 80.75, suggesting a potential upside of 141.09%. Given Alliance Pharma's higher possible upside, equities research analysts plainly believe Alliance Pharma is more favorable than Beximco Pharmaceuticals.
71.0% of Alliance Pharma shares are owned by institutional investors. Comparatively, 1.6% of Beximco Pharmaceuticals shares are owned by institutional investors. 11.7% of Alliance Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 6.0%. Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 7.9%. Alliance Pharma pays out -20,000.0% of its earnings in the form of a dividend. Beximco Pharmaceuticals pays out 3,750.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
In the previous week, Alliance Pharma had 1 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 1 mentions for Alliance Pharma and 0 mentions for Beximco Pharmaceuticals. Beximco Pharmaceuticals' average media sentiment score of 0.88 beat Alliance Pharma's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the news media.
Summary
Beximco Pharmaceuticals beats Alliance Pharma on 11 of the 19 factors compared between the two stocks.
Get Alliance Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for APH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alliance Pharma Competitors List
Related Companies and Tools
